Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ARargenx SE logo

argenx SE (ARGX)

NASDAQ Global Select · Currency in USD
$873.71 ▼ -2.06 (-0.23%)
At close: Oct 23, 4:00 PM ET. Market closed.
$872.01 ▼ -1.70 (-0.19%)
After hours: Oct 23, 7:37 PM ET

Summary

Previous Close
$875.76
Open
$875.98
Day's Range
$866.06 – $887.07
52 Week Range
$661.85 – $1,072.75
Volume
295,815
Avg. Volume
350,437
Market Cap
$54.94B
Beta (5Y Monthly)
-0.02
PE Ratio (TTM)
31.76
EPS (TTM)
$27.41
Earnings Date
Feb 25, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1,133.33

Profile: argenx SE

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,863
CEO
Karen Massey
Website
argenx.com

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions.

Earnings

Next report: Thu, Feb 25, 2027
EPS estimate $7.76 · Revenue est. $3.35B
DateEst.Actual
Jul 30, 2026$7.44$7.80Beat
May 7, 2026$5.16$5.90Beat
Oct 30, 2025$4.37$5.18Beat
May 8, 2025$2.32$2.58Beat
Oct 31, 2024$0.10$1.39Beat
May 9, 2024-$0.71-$1.04Miss

Analyst view

Consensus price target
$1,133.33 ▲ +29.7%
Range $861.00 – $1,400.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Get free alerts on ARGX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.